iCAD, Inc. (NASDAQ:ICAD) Short Interest Update

iCAD, Inc. (NASDAQ:ICAD) was the recipient of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 233,000 shares, a decline of 6.5% from the October 31st total of 249,100 shares. Based on an average daily volume of 203,500 shares, the short-interest ratio is presently 1.1 days. Currently, 0.9% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a report on Thursday, November 21st.

iCAD Price Performance

NASDAQ ICAD traded up $0.03 during trading hours on Monday, reaching $1.76. The company’s stock had a trading volume of 152,391 shares, compared to its average volume of 185,410. The firm has a market capitalization of $46.71 million, a price-to-earnings ratio of -13.54 and a beta of 1.47. The company’s 50-day moving average is $1.73 and its two-hundred day moving average is $1.55. iCAD has a 1-year low of $1.18 and a 1-year high of $2.65.

Institutional Investors Weigh In On iCAD

Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC lifted its holdings in iCAD by 55.6% during the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after purchasing an additional 7,604 shares in the last quarter. Perritt Capital Management Inc boosted its holdings in iCAD by 14.2% in the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after buying an additional 19,917 shares during the last quarter. Finally, Essex LLC purchased a new stake in iCAD during the 3rd quarter worth approximately $216,000. Institutional investors and hedge funds own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.